Alumis is firmly in focus after announcing positive topline results from two Phase 3 trials (ONWARD1 and ONWARD2) evaluating envudeucitinib , its next-generation oral TYK2 inhibitor, in ...

WhatsApp, with over two billion members worldwide, is taking a massive stride forward with the implementation of the ...

Scientists are trying to tame the chaos of modern artificial intelligence by doing something very old fashioned: drawing a ...

Entering 2026, fluctuations in global supply chains have pushed the focus of corporate management from "scale expansion" to ...

Cyclerion Strengthens Development of Closed-Loop Anesthetic Platform through Strategic Collaboration Agreement with Medsteer ...